{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:54:44Z","timestamp":1779926084134,"version":"3.53.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA230155"],"award-info":[{"award-number":["K08 CA230155"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Life expectancy (LE) is essential for triage between aggressive and conservative management for all prostate cancer risk subtypes. We sought to investigate differences in how Black and Hispanic men interpret LE in treatment decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used targeted crowdsourcing to sample a cohort reflecting sociodemographics of a US prostate cancer population. Subjects completed a conjoint analysis exercise where they iteratively chose between aggressive treatment versus conservative management across levels of 4 tradeoffs\u2014tumor risk (lives saved by aggressive treatment at 5\/10\/20\u2009year); erectile dysfunction; urinary incontinence; and irritative urinary symptoms\u2014while considering their LE as calculated by the Prostate Cancer Comorbidity Index. Multinomial conditional logistic regression compared odds of choosing aggressive vs. conservative treatment across LEs ranging from 0 to 20 years overall and across racial\/ethnic subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 2046 men, 435 (22%) were Black and 230 (11%) were Hispanic. Across all men, the odds of aggressive treatment choice increased by 17% for every 5\u2009years of additional LE (OR\u2009=\u20091.17, 95%CI\u2009=\u20091.12\u20131.22,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Men were significantly more likely to choose aggressive treatment at LE\u2009&gt;\u200913\u2009y and non-aggressive treatment at LE\u2009\u2264\u200910\u2009y. Among Black men, LE was not associated with treatment choice, as they consistently preferred aggressive treatment across all LE categories. Among Hispanic men, increased LE was associated with a higher likelihood of choosing aggressive treatment, with significant preference for aggressive treatment observed only when LE\u2009&gt;\u200910 years. These patterns remained consistent when further stratified by tumor risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LE had no impact on treatment decisions in Black men, in contrast to other races and ethnicities. Future research is needed to identify reasons for this phenomenon and to inform culturally relevant approaches to communicating competing mortality risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-025-01036-w","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:44:13Z","timestamp":1759841053000},"page":"397-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Racial and ethnic differences in valuation of life expectancy in prostate cancer treatment decision making"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0388-1670","authenticated-orcid":false,"given":"John M.","family":"Masterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4286-2544","authenticated-orcid":false,"given":"Renning","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-3473","authenticated-orcid":false,"given":"Adam","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-6749","authenticated-orcid":false,"given":"Yaw A.","family":"Nyame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-3372","authenticated-orcid":false,"given":"Chad","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-3272","authenticated-orcid":false,"given":"Timothy J.","family":"Daskivich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"1036_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.7326\/0003-4819-158-10-201305210-00005","volume":"158","author":"TJ Daskivich","year":"2013","unstructured":"Daskivich TJ, Fan K-H, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158:709\u201317.","journal-title":"Ann Intern Med"},{"key":"1036_CR2","unstructured":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management | Journal of Urology. https:\/\/www.auajournals.org\/doi\/10.1097\/JU.0000000000002757 (accessed 9 Dec2022)."},{"key":"1036_CR3","doi-asserted-by":"publisher","first-page":"E243","DOI":"10.1016\/j.ijrobp.2017.06.1184","volume":"99","author":"SB Johnson","year":"2017","unstructured":"Johnson SB, Lester-Coll NH, Bledsoe TJ, Kelly JR, Stahl JM, Nath SK, et al. Undertreatment of elderly men with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;99:E243.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1036_CR4","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/cncr.25751","volume":"117","author":"TJ Daskivich","year":"2011","unstructured":"Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011;117:2058\u201366.","journal-title":"Cancer"},{"key":"1036_CR5","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1056\/NEJMc1900333","volume":"380","author":"S Butler","year":"2019","unstructured":"Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, et al. Active surveillance for low-risk prostate cancer in black patients. N Engl J Med. 2019;380:2070\u20132.","journal-title":"N Engl J Med"},{"key":"1036_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jnci\/94.5.334","volume":"94","author":"VL Shavers","year":"2002","unstructured":"Shavers VL. Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. JNCI J Natl Cancer Inst. 2002;94:334\u201357.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1036_CR7","first-page":"56","volume":"14","author":"BR Kennedy","year":"2007","unstructured":"Kennedy BR, Mathis CC, Woods AK. African Americans and their distrust of the health care system: healthcare for diverse populations. J Cult Divers. 2007;14:56\u201360.","journal-title":"J Cult Divers"},{"key":"1036_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/JU.0000000000001385","volume":"205","author":"ME DeWitt-Foy","year":"2021","unstructured":"DeWitt-Foy ME, Gam K, Modlin C, Kim SP, Abouassaly R. Race, decisional regret and prostate cancer beliefs: identifying targets to reduce racial disparities in prostate cancer. J Urol. 2021;205:426\u201333.","journal-title":"J Urol"},{"key":"1036_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X08327396","volume":"29","author":"PKJ Han","year":"2009","unstructured":"Han PKJ, Klein WMP, Lehman TC, Massett H, Lee SC, Freedman AN. Laypersons\u2019 responses to the communication of uncertainty regarding cancer risk estimates. Med Decis Mak Int J Soc Med Decis Mak. 2009;29:391\u2013403.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"1036_CR10","first-page":"4","volume":"12","author":"PKJ Han","year":"2009","unstructured":"Han PKJ, Lehman TC, Massett H, Lee SJC, Klein WMP, Freedman AN. Conceptual problems in laypersons\u2019 understanding of individualized cancer risk: a qualitative study. Health Expect Int J Public Particip Health Care Health Policy. 2009;12:4\u201317.","journal-title":"Health Expect Int J Public Particip Health Care Health Policy"},{"key":"1036_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.urology.2016.02.057","volume":"93","author":"TJ Daskivich","year":"2016","unstructured":"Daskivich TJ, Lai J, Dick AW, Setodji CM, Hanley JM, Litwin MS, et al. Questioning the 10-year life expectancy rule for high-grade prostate cancer: comparative effectiveness of aggressive vs nonaggressive treatment of high-grade disease in older men with differing comorbid disease burdens. Urology. 2016;93:68\u201376.","journal-title":"Urology"},{"key":"1036_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2217\/cer.13.34","volume":"2","author":"DA Barocas","year":"2013","unstructured":"Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013;2:445\u201360.","journal-title":"J Comp Eff Res"},{"key":"1036_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1209978","volume":"368","author":"MJ Resnick","year":"2013","unstructured":"Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436\u201345.","journal-title":"N Engl J Med"},{"key":"1036_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/jncimonographs\/lgs025","volume":"2012","author":"L Holmberg","year":"2012","unstructured":"Holmberg L, Bill-Axelson A, Steineck G, Garmo H, Palmgren J, Johansson E, et al. Results from the scandinavian prostate cancer group trial number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting. J Natl Cancer Inst Monogr. 2012;2012:230\u20133.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1036_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cct.2008.08.002","volume":"30","author":"TJ Wilt","year":"2009","unstructured":"Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer Intervention Versus Observation Trial:VA\/NCI\/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30:81\u201387.","journal-title":"Contemp Clin Trials"},{"key":"1036_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.juro.2015.01.081","volume":"194","author":"TJ Daskivich","year":"2015","unstructured":"Daskivich TJ, Kwan L, Dash A, Saigal C, Litwin MS. An age adjusted comorbidity index to predict long-term, other cause mortality in men with prostate cancer. J Urol. 2015;194:73\u201378.","journal-title":"J Urol"},{"key":"1036_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2296-7-21","volume":"7","author":"NS Morris","year":"2006","unstructured":"Morris NS, MacLean CD, Chew LD, Littenberg B. The Single Item Literacy Screener: Evaluation of a brief instrument to identify limited reading ability. BMC Fam Pr. 2006;7:21.","journal-title":"BMC Fam Pr"},{"key":"1036_CR18","unstructured":"Cancer of the Prostate - Cancer Stat Facts. SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html (accessed 17 Feb2023)."},{"key":"1036_CR19","doi-asserted-by":"publisher","first-page":"e2031349","DOI":"10.1001\/jamanetworkopen.2020.31349","volume":"3","author":"SL Washington","year":"2020","unstructured":"Washington SL, Jeong CW, Lonergan PE, Herlemann A, Gomez SL, Carroll PR, et al. Regional variation in active surveillance for low-risk prostate cancer in the US. JAMA Netw Open. 2020;3:e2031349.","journal-title":"JAMA Netw Open"},{"key":"1036_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jama.2018.19941","volume":"321","author":"BA Mahal","year":"2019","unstructured":"Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D\u2019Amico AV, et al. Use of Active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010\u20132015. JAMA. 2019;321:704\u20136.","journal-title":"JAMA"},{"key":"1036_CR21","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.2012.47.0302","volume":"31","author":"D Sundi","year":"2013","unstructured":"Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol J Am Soc Clin Oncol. 2013;31:2991\u20137.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"1036_CR22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/pros.21314","volume":"71","author":"G Chornokur","year":"2011","unstructured":"Chornokur G, Dalton K, Borysova M, Kumar N. Disparities at presentation, diagnosis, treatment and survival in African American men, affected by prostate cancer. Prostate. 2011;71:985\u201397.","journal-title":"Prostate"},{"key":"1036_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.6004\/jnccn.2014.0072","volume":"12","author":"JL Mohler","year":"2014","unstructured":"Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D\u2019Amico AV, et al. Prostate cancer, version 2.2014. J Natl Compr Cancer Netw JNCCN. 2014;12:686\u2013718.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"1036_CR24","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1002\/cncr.27379","volume":"118","author":"GB Taksler","year":"2012","unstructured":"Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118:4280\u20139.","journal-title":"Cancer"},{"key":"1036_CR25","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.2105\/AJPH.94.12.2084","volume":"94","author":"RL Johnson","year":"2004","unstructured":"Johnson RL, Roter D, Powe NR, Cooper LA. Patient race\/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health. 2004;94:2084\u201390.","journal-title":"Am J Public Health"},{"key":"1036_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0029-6554(96)80020-0","volume":"44","author":"BD Powe","year":"1996","unstructured":"Powe BD. Cancer fatalism among African-Americans: a review of the literature. Nurs Outlook. 1996;44:18\u201321.","journal-title":"Nurs Outlook"},{"key":"1036_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/00002820-200312000-00005","volume":"26","author":"BD Powe","year":"2003","unstructured":"Powe BD, Finnie R. Cancer fatalism: the state of the science. Cancer Nurs. 2003;26:454\u201365. quiz 466\u2013467.","journal-title":"Cancer Nurs"},{"key":"1036_CR28","first-page":"998","volume":"16","author":"J Niederdeppe","year":"2007","unstructured":"Niederdeppe J, Levy AG. Fatalistic beliefs about cancer prevention and three prevention behaviors. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2007;16:998\u20131003.","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"1036_CR29","first-page":"153","volume":"17","author":"AE Abra\u00eddo-Lanza","year":"2007","unstructured":"Abra\u00eddo-Lanza AE, Viladrich A, Fl\u00f3rez KR, C\u00e9spedes A, Aguirre AN, De La Cruz AA. Commentary: fatalismo reconsidered: a cautionary note for health-related research and practice with Latino populations. Ethn Dis. 2007;17:153\u20138.","journal-title":"Ethn Dis"},{"key":"1036_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10810730600637426","volume":"11","author":"K Viswanath","year":"2006","unstructured":"Viswanath K, Breen N, Meissner H, Moser RP, Hesse B, Steele WR, et al. Cancer knowledge and disparities in the information age. J Health Commun. 2006;11:1\u201317.","journal-title":"J Health Commun"},{"key":"1036_CR31","first-page":"217","volume":"10","author":"V Carpenter","year":"1995","unstructured":"Carpenter V, Colwell B. Cancer knowledge, self-efficacy, and cancer screening behaviors among Mexican-American women. J Cancer Educ J Am Assoc Cancer Educ. 1995;10:217\u201322.","journal-title":"J Cancer Educ J Am Assoc Cancer Educ"},{"key":"1036_CR32","doi-asserted-by":"crossref","unstructured":"Cancer Fatalism: Attitudes Toward Screening and Care. In: Psychological Aspects of Cancer. Springer International Publishing: Cham, 2022, pp 301-18.","DOI":"10.1007\/978-3-030-85702-8_18"},{"key":"1036_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2009.0002","volume":"7","author":"JE Montie","year":"2009","unstructured":"Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, et al. Bladder cancer. J Natl Compr Cancer Netw JNCCN. 2009;7:8\u201339.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"1036_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health J Int Soc Pharmacoecon Outcomes Res. 2011;14:403\u201313.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"key":"1036_CR35","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/0272989X19873667","volume":"39","author":"RM Kaplan","year":"2019","unstructured":"Kaplan RM, Crespi CM, Dahan E, Saucedo JD, Pagan C, Saigal CS. Comparison of rating scale, time tradeoff, and conjoint analysis methods for assessment of preferences in prostate cancer. Med Decis Mak Int J Soc Med Decis Mak. 2019;39:816\u201326.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"1036_CR36","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.jacr.2024.04.030","volume":"21","author":"JR Dallmer","year":"2024","unstructured":"Dallmer JR, Luu M, Saouaf R, Spiegel B, Freedland SJ, Daskivich TJ. Patient perceptions of standardized risk language used in ACR prostate MRI PI-RADS scores. J Am Coll Radio. 2024;21:1634\u201342.","journal-title":"J Am Coll Radio"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01036-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:42:01Z","timestamp":1779331321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01036-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01036-w","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the Cedars-Sinai IRB (STUDY00000982). All participants provided written or verbal informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}